Adlai Nortye expands AN4035 trial with Lilly and Merck KGaA support
On October 15, 2026, Adlai Nortye announced research and drug-supply arrangements with Eli Lilly and Merck KGaA for its AN4035 cancer treatment. The ongoing global Phase I study will test AN4035 alone and alongside cetuximab in patients with CEACAM5-enriched, RAS-driven solid tumors. Lilly will provide cetuximab to U.S. trial locations at no cost, while Merck KGaA will cover sites in Australia and China without charge.
Why it matters
The arrangements let Adlai Nortye add cetuximab combination arms without paying for the drug supplied under the agreements. Adlai Nortye remains the trial sponsor, while the materials report no purchase price, milestone payment or equity investment for Lilly or Merck KGaA.
Key facts
- 1Adlai Nortye entered the arrangements with Eli Lilly and Merck KGaA on October 15, 2026. financial-news.co.uk
- 2AN4035 will be evaluated as both a standalone treatment and in combination with cetuximab in an ongoing global Phase I study. rttnews.com
- 3Lilly is providing cetuximab at no cost to U.S. trial sites, and Merck KGaA is supplying it without charge in Australia and China. tipranks.com
- 4Adlai Nortye remains the sponsor of the trial. rttnews.com
Open questions
- The materials do not disclose a purchase price, milestone payment or equity stake for the arrangements.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.